SCHEMBL192389

SCHEMBL192389

O=C(O)Cc1ccc(Cl)s1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.54
MAPT P10636 3/20 0.54
KMT2A Q03164 5/20 0.50
MMP8 P22894 1/20 0.50
MMP12 P39900 1/20 0.50
MMP13 P45452 1/20 0.50
L3MBTL1 Q9Y468 3/20 0.49
DAO P14920 1/20 0.48
FFAR1 O14842 1/20 0.47
ALDH1A1 P00352 3/20 0.47
HTT P42858 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MEN1 O00255 2/20 0.46
USP2 O75604 1/20 0.46
HSD17B10 Q99714 1/20 0.46
GSK3B P49841 1/20 0.44
TDP1 Q9NUW8 2/20 0.44
POLB P06746 1/20 0.44
APEX1 P27695 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10998190 0.98 HPGD (0.53) HPGDMAPTKMT2AMMP8MMP12
Methyl Alcohol SCHEMBL11791471 0.96 HPGD (0.51) HPGDMAPTKMT2AMMP8MMP12
SCHEMBL68973 0.84 HPGD (0.59) HPGDMAPTKMT2AL3MBTL1ALDH1A1
SCHEMBL7472736 0.83 ALDH1A1 (0.47) HPGDMAPTKMT2AMMP8MMP12
SCHEMBL4239545 0.81 ALDH1A1 (0.50) HPGDMAPTKMT2AMMP8MMP12
SCHEMBL4086194 0.81 F2 (0.52) HPGDMAPTKMT2AMMP8MMP12
SCHEMBL11722373 0.81 ALDH1A1 (0.46) HPGDMAPTKMT2AMMP8MMP12
SCHEMBL27761777 0.80 FFAR1 (0.43) HPGDMAPTKMT2AMMP8MMP12
SCHEMBL11623289 0.80 MMP8 (0.52) HPGDMAPTKMT2AMMP8MMP12
SCHEMBL4388131 0.79 FFAR1 (0.60) HPGDMAPTKMT2AMMP8MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4692057-A1 NOVEL B0AT1 INHIBITOR Mitsubishi Tanabe Pharma Corporation (JP) 2026-02-11 EP disclosed
US-20260001849-A1 NOVEL B0AT1 INHIBITOR MITSUBISHI TANABE PHARMA CORPORATION (JP) 2026-01-01 US disclosed
US-20250152588-A1 HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2025-05-15 US disclosed
CN-118772070-A Quinazoline derivative and preparation method and application thereof 天津济坤医药科技有限公司 2024-10-15 CN disclosed
WO-2024210198-A1 NOVEL B0AT1 INHIBITOR 田辺三菱製薬株式会社 2024-10-10 WO disclosed
US-20220226326-A1 HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2022-07-21 US disclosed
CN-110225911-B Oxadiazolone transient receptor potential channel inhibitors 豪夫迈·罗氏有限公司 2022-04-05 CN disclosed
EP-3544979-B1 OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS HOFFMANN LA ROCHE (CH) 2021-08-04 EP disclosed
EP-3544979-B1 OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS HOFFMANN LA ROCHE (CH) 2021-08-04 EP disclosed
US-10913742-B2 Oxadiazolones as transient receptor potential channel inhibitors GENENTECH, INC. (US) 2021-02-09 US disclosed
CN-1046525-A 3-SUBSTITUTED-2-OXINDOLE DERIVATIVES PFIZER (US) 1990-10-31 CN disclosed
EP-0393936-A1 3-substituted-2-oxindole derivatives as antiinflammatory agents PFIZER INC. (US) 1990-10-24 EP disclosed
EP-0259480-A4 SUBSTITUTED 2-AMINOTETRALINS. NELSON RES & DEV COMPANY (US) 1988-07-25 EP disclosed
EP-0259480-A1 SUBSTITUTED 2-AMINOTETRALINS Whitby Research Incorporated (US) 1988-03-16 EP disclosed
US-4722933-A GLAUCOMA TREATMENT NELSON RESEARCH & DEVELOPMENT CO. (US) 1988-02-02 US disclosed
WO-1987005602-A1 SUBSTITUTED 2-AMINOTETRALINS NELSON RESEARCH AND DEVELOPMENT COMPANY (US) 1987-09-24 WO disclosed
EP-0011279-B1 PROCESS FOR THE PREPARATION OF AROMATICALLY SUBSTITUTED ACETIC ACIDS SAGAMI CHEMICAL RESEARCH CENTER (JP) 1982-05-05 EP disclosed
US-4268442-A REACTING AN AROMATIC ALKEHYDE WITH A TRIHALOMETHANE AND AN ALKANETHIOL IN THE PRESENCE OF A BASE AND AN APROTIC SOLVENT SAGAMI CHEMICAL RESEARCH CENTER (JP) 1981-05-19 US disclosed
EP-0011279-A1 Process for the preparation of aromatically substituted acetic acids SAGAMI CHEMICAL RESEARCH CENTER (JP) 1980-05-28 EP disclosed
US-4093622-A Pyridine esters of cyclopropane-carboxylic acid ZOECON CORPORATION (US) 1978-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001849-A1 NOVEL B0AT1 INHIBITOR BCAT1, BCAT2, BHMT HPGD 2913/4885MAPT 787/4885KMT2A 433/4885
US-10913742-B2 Oxadiazolones as transient receptor potential channel inhibitors TRPA1, TRPV1, TRPV3 HPGD 346/4885MAPT 3057/4885KMT2A 4562/4885
US-20220226326-A1 HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS AKT1, AKT2, AKT1S1 HPGD 1065/4885MAPT 3868/4885KMT2A 1884/4885
US-20250152588-A1 HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS AKT1, AKT2, AKT1S1 HPGD 1065/4885MAPT 3868/4885KMT2A 1884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.